Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Conditions
Keywords
Subfoveal Choroidal Neovascularization
Brief summary
This research study will examine the safety and effectiveness of ONS-5010 in participants with AMD. The goal is to prevent vision loss by evaluating the effectiveness of ONS-5010 as compared with ranibizumab.
Interventions
BIOLOGICALbevacizumab
1.25 mg, intravitreal injection
BIOLOGICALranibizumab
0.5mg, intravitreal injection
Sponsors
Outlook Therapeutics, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Active primary Subfoveal Choroidal Neovascularization lesions secondary to Age-related macular degeneration (AMD) in the study eye * Best corrected visual acuity of 25-67 letters read (20/50 to 20/320 Snellen equivalent) * Study eye must: * Have active leakage on Fluorescein Angiogram involving the fovea * Have edema involving the fovea * Be free of scarring, fibrosis, or atrophy involving the central foveal zone
Exclusion criteria
* Previous subfoveal focal laser photocoagulation in the study eye * Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1-month preceding randomization * Any concurrent intraocular condition in the study eye that may require medical or surgical intervention or contribute to vision loss within 1 year * Active intraocular inflammation (grade trace or above) in the study eye * Current vitreous haemorrhage in the study eye * Polypoidal choroidal vasculopathy (PCV) in the study eye * History of idiopathic or autoimmune-associated uveitis in either eye * Infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye * Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥30 mmHg despite treatment with anti-glaucoma medication) * Premenopausal women not using adequate contraception * Current treatment for active systemic infection * Known allergy to any component of the study drug or history of allergy to fluorescein , not amenable to treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Subjects Who Gain 15 or More Letters in Best Corrected Visual Acuity (BCVA) | 11 months | BCVA to be assessed as letters read using the Early Treatment Diabetic Retinopathy Study (ETDRS) charts. A positive change represents an improvement in visual acuity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean Change in the Best Corrected Visual Acuity | 11 months | BCVA to be assessed as letters read using the ETDRS charts. A positive change represents an improvement in visual acuity. |
| Proportion of Participants Who Gain at Least 10 Letters in the Best Corrected Visual Acuity | 11 months | BCVA to be assessed as letters read using the ETDRS charts. A positive change represents an improvement in visual acuity. |
| Proportion of Participants Who Gain at Least 5 Letters in the Best Corrected Visual Acuity | 11 months | BCVA to be assessed as letters read using the ETDRS charts. A positive change represents an improvement in visual acuity. |
| Proportion of Participants Who Lose Fewer Than 15 Letters in the Best Corrected Visual Acuity | 11 months | BCVA to be assessed as letters read using the ETDRS charts. A negative change represents a decrease in visual acuity. |
| Proportion of Participants With Visual-acuity Snellen Equivalent of 20/200 or Worse | 11 months | — |
Countries
United States
Contacts
STUDY_DIRECTORJennifer M Kissner, PhD
Outlook Therapeutics, Inc.
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 78.8 years STANDARD_DEVIATION 8.3 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants |
| Race (NIH/OMB) White | 223 Participants |
| Sex: Female, Male Female | 67 Participants |
| Sex: Female, Male Male | 46 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 3 / 113 | 2 / 115 |
| other Total, other adverse events | 31 / 113 | 34 / 115 |
| serious Total, serious adverse events | 14 / 113 | 16 / 115 |
Outcome results
None listed